Bratislava Medical Journal Vol.119, No.4, p.191-197, 2018

Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.119, No.4, p.191-197, 2018
Title: New biological agents in the treatment of multiple sclerosis
Author: M. Buc

Abstract: Multiple sclerosis (MS) is an inflammatory disease induced by autoimmune processes. Their understanding has resulted in an introduction of biological agents to its treatment. Interferon beta and glatiramer acetate have been in clinical practice for more than 20 years. Nowadays, novel biologics, which target molecules involved in immunopathological processes more specifically have entered the scene. They are represented by monoclonal antibodies binding to molecules VLA4 (natalizumab), CD20 (ocrelizumab), CD52 (alemtuzumab) or alpha subunit of IL-2 receptor (daclizumab) or by small molecules such as those modulating the receptors involved in regulation of lymphocyte migration (fingolimod, ozanimod) or in induction of lymphopenia by apoptosis (dimethyl fumarate, cladribine). In the article, we shortly describe their efficacies, adverse reactions and perspectives of a future development in MS biologics. A treatment of neuromyelitis optica by monoclonal antibodies (rituximab, aquaporumab) is given too (Tab. 1, Fig. 2, Ref. 71).

Keywords: multiple sclerosis, neuromyelitis optica, monoclonal antibodies, migration of T and B cells, JC virus, PML, IRIS
	Published online: 09-Apr-2018
Year: 2018, Volume: 119, Issue: 4	Page From: 191, Page To: 197
doi:10.4149/BLL_2018_035
	download file

Aepress.sk